Investigational drug · Phase 3
Litifilimab
Also called: BIIB059
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
8
Any phase or sponsor naming "Litifilimab"
First trial start
2021
May 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Litifilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus
- Lupus Erythematosus, Systemic
- Systemic Lupus Erythematosus (SLE)
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Litifilimab" as an intervention, largest first.
- A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)Pivotal-lookingEnrolling by invitation
BiogenBiogen (BIIB)
NCT05352919 · 864 participants (planned) · Start Jun 10, 2022 · Primary completion May 3, 2032
Drug: Litifilimab; Litifilimab-matching placebo · For: Systemic Lupus Erythematosus (SLE)
Sites: Phoenix, Arizona; Beverly Hills, California; Huntington Beach, California · 214 sites in all
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT04961567 · 562 participants · Start Jul 16, 2021 · Primary completion Sep 27, 2026
Drug: Litifilimab; Placebo · For: Lupus Erythematosus, Systemic
Sites: Birmingham, Alabama; Glendale, Arizona; Huntington Beach, California · 177 sites in all
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT04895241 · 548 participants · Start May 25, 2021 · Primary completion Sep 30, 2026
Drug: Litifilimab; Placebo · For: Lupus Erythematosus, Systemic
Sites: Homewood, Alabama; Beverly Hills, California; Los Angeles, California · 164 sites in all
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT05531565 · 450 participants (planned) · Start Sep 13, 2022 · Primary completion Oct 20, 2026
Drug: Litifilimab; Placebo · For: Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 315 sites in all
- A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different WaysPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT06741657 · 404 participants · Start Jan 2, 2025 · Primary completion Mar 10, 2026
Drug: Litifilimab · For: Healthy Volunteer
Sites: Las Vegas, Nevada; Austin, Texas
- A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusPivotal-lookingEnrolling by invitation
BiogenBiogen (BIIB)
NCT06044337 · 306 participants (planned) · Start Oct 3, 2023 · Primary completion Jun 26, 2029
Drug: BIIB059 (litifilimab) · For: Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 104 sites in all
- Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02847598 · 264 participants · Start Oct 20, 2016 · Primary completion Aug 28, 2019
Drug: BIIB059 (litifilimab); Placebo · For: Systemic Lupus Erythematosus; Active Cutaneous Lupus Erythematosus
Sites: Anniston, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 128 sites in all
- Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus ErythematosusPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02106897 · 109 participants · Start Apr 30, 2014 · Primary completion May 24, 2016
Drug: BIIB059 (litifilimab); Placebo · For: Systemic Lupus Erythematosus; Healthy Volunteers
Sites: Anniston, Alabama; Birmingham, Alabama; Orlando, Florida · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Update on biologics in SLE.
Delai M, Kyttaris VC · Curr Opin Rheumatol 2026
- Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study.
van Vollenhoven RF, Furie RA, Kalunian K, et al. · Lupus Sci Med 2026
- Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST.
Merola JF, Werth VP, Chong BF, et al. · J Am Acad Dermatol 2026
- Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review.
Jonnalagadda A, Richmond RL, Pathak GN, et al. · Dermatol Ther (Heidelb) 2026
- Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.
van Vollenhoven R · J Intern Med 2026
- Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.
Werth VP, Merola JF, Furie R, et al. · J Eur Acad Dermatol Venereol 2026
Also in development for Subacute Cutaneous Lupus Erythematosus
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Biogen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.